

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Originally Presented) Monoclonal antibody 4G9 produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs).
2. (Originally Presented) The monoclonal antibody or antigen binding fragment thereof of claim 1, which specifically binds to serum-AGE protein, serum-AGE lipids, serum-AGE peptides, LDL-AGE, Hb-AGE, or collagen-AGE.
3. (Currently Amended) A humanized or ~~chimetic~~ chimeric human-murine antibody of the monoclonal antibody of claim 1.
4. (Originally Presented) The antigen-binding fragment of the monoclonal antibody of claim 1, selected from the group consisting of a single chain Fv fragment, an F(ab')fragment, an F(ab) fragment, and an F(ab')2 fragment.
5. (Originally Presented) The monoclonal antibody or fragment thereof of claim 1, which is a murine IgG isotype antibody.
6. (Originally Presented) The labeled antibody wherein the antibody is the antibody of claim 1.
7. (Originally Presented) A hybridoma deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626.
8. (Originally Presented) A pharmaceutical composition containing an anti-AGE antibody in combination with a pharmaceutically acceptable carrier; wherein said anti-AGE antibody is the monoclonal antibody in accordance with any of claims 1-3 or 4.
9. (Previously Amended) A monoclonal antibody, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs), wherein the antibody or fragment is selected such that antigen binding measured by binding competition by 6-

aminocaproic acid browned with glucose matches that of a reference binding moiety which is monoclonal antibody 4G9 produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626 or a fragment thereof corresponding to the antigen binding fragment.

10. (Previously Cancelled).

11. (Originally Presented) The monoclonal antibody or antigen binding fragment thereof of claim 9, which specifically binds to serum-AGE protein, serum-AGE lipids, serum-AGE peptides, LDL-AGE, Hb-AGE, or collagen-AGE.

12. (Currently Amended) A humanized or ~~chimetic~~ chimeric human-murine antibody of the monoclonal antibody of claim 9.

13. (Originally Presented) The antigen-binding fragment of the monoclonal antibody of claim 9, selected from the group consisting of a single chain Fv fragment, an F(ab')fragment, an F(ab) fragment, and an F(ab')2 fragment.

14. (Originally Presented) The monoclonal antibody or fragment thereof of claim 9, which is a murine IgG isotype antibody.

15. (Originally Presented) The labeled antibody wherein the antibody is the antibody of claim 9.

16. (Previously Amended) A pharmaceutical composition containing an anti-AGE antibody in combination with a pharmaceutically acceptable carrier; wherein said anti-AGE antibody is the monoclonal antibody in accordance with any of claims 9, 11-12 or 13.